PARIS, France and CAMBRIDGE, MA, US – 16 2017 may – 18 pm CEST – Lysogene (FR0013233475 – LYS), a biopharmaceutical company pioneering and specializing in gene therapy targeting the rare disease of the central nervous system, today announces the appointment of Philippe Mendels-Flanders for the post of Chief Operating Officer. Philippe Mendels-Flandre comes to reinforce the management team of Lysogene to support the company in its new strategic issues of growth. For this purpose, Philippe Mendels-Flandre will supervise all financial activities, partnerships and development projects of the Company. Philippe is a member of the Executive Committee.
Download the free guide
Boost your gains
Karen Aiach, CEO of Lysogene, is delighted: “We had a strong will of strengthening and structuring of our management team. While we will enter into clinical study phase II/III in the Mucopolysaccharidosis Type IIIA in the near future, the expertise and the leadership of Philippe Mendels-Flandre will be essential to support our growth strategy “.
Philippe Mendels-Flandre was previously the General Manager EAMEA at Shire – pharmaceutical group specialized in rare diseases, which he joined in 2000, when the company was called Baxter and Baxalta. Philippe has held important functions within the group, both at a strategic level commercial, industrial or financial. Throughout his career Philip has developed a significant expertise in multidisciplinary, in particular in the direction of cross-functional projects and international. Philippe has among other things contributed to the integration of Baxalta within Shire and to the group’s growth in the emerging countries.
About Lysogene
Lysogene is a biotechnology corporation clinical stage pioneer in the basic research and the clinical development of gene therapies using vectors derived from adeno-associated viruses to treat rare diseases and life-threatening CNS of the child, for which there is today, to the knowledge of the Company, no treatment. Since 2009, Lysogene has put in place a strong platform and a large network, with innovative products in the MPS-IIIA and in the gangliosidosis GM1. Each of the products developed by Lysogene, LYS-SAF302 and LYS-GM101, has orphan drug designations by the FDA and the EMA, and the designation of rare disease pediatric by the FDA.
Lysogene is listed on the regulated market of Euronext Paris of Euronext Paris (ISIN code : FR0013233475). More information : www.lysogene.com.
Download the free guide
Boost your gains
